Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)
Valneva SE's (VALN) quarterly Total Non-Current Liabilities came in at $235.4 million in Q1 2026, up 11.47% year-on-year from $211.2 million in Q1 2025, and up 1.46% quarter-over-quarter from $232.0 million in Q4 2025.
Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $235.4 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $235.4 million, up 11.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.4 million (up 11.47% YoY), and the FY2025 annual result was $232.0 million, up 6.34% from the prior year.
- Total Non-Current Liabilities came in at $235.4 million for Q1 2026 at Valneva SE, up from $232.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $298.6 million in Q1 2022 to a low of $120.7 million in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $208.6 million (2024), against an average of $192.7 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 60.14% in 2022 and surged 76.52% in 2024, its largest moves.
- Valneva SE's Total Non-Current Liabilities stood at $126.7 million in 2022, then surged by 46.91% to $186.1 million in 2023, then increased by 17.26% to $218.2 million in 2024, then rose by 6.34% to $232.0 million in 2025, then grew by 1.46% to $235.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $235.4 million (Q1 2026), $232.0 million (Q4 2025), and $172.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 42,980.09 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 64.76 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 235.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 235.43 Mn |
| Dec 31, 2025 | 232.03 Mn |
| Sep 30, 2025 | 172.17 Mn |
| Jun 30, 2025 | 181.72 Mn |
| Mar 31, 2025 | 211.21 Mn |
| Dec 31, 2024 | 218.21 Mn |
| Sep 30, 2024 | 208.65 Mn |
| Jun 30, 2024 | 213.01 Mn |
| Mar 31, 2024 | 214.57 Mn |
| Dec 31, 2023 | 186.09 Mn |
| Sep 30, 2023 | 157.70 Mn |
| Jun 30, 2023 | 120.68 Mn |
| Mar 31, 2023 | 130.90 Mn |
| Dec 31, 2022 | 126.67 Mn |
| Sep 30, 2022 | 160.20 Mn |
| Jun 30, 2022 | 208.85 Mn |
| Mar 31, 2022 | 298.60 Mn |
| Dec 31, 2021 | 317.78 Mn |
| Dec 31, 2020 | 233.54 Mn |